Outcomes in paediatric metastatic rhabdomyosarcoma: Results of The International Society of Paediatric Oncology (SIOP) study MMT-98

European Journal of Cancer

Volumn 46, Issue 9, 2010, Pages 1588-1595

  McDowell, Heather P ^a   Foot, Annabel B M ^b   Ellershaw, Caroline ^c   Machin, David ^c   Giraud, Cécile ^d   Bergeron, Christophe ^d  

^a ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

^b BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

^d CENTRE LÉON BÉRARD   (France)

Author keywords

High dose and maintenance chemotherapy; Metastatic rhabdomyosarcoma

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW METASTASIS; BONE METASTASIS; BRAIN DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHILD; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FATALITY; DRUG MEGADOSE; DRUG RESPONSE; EVENT FREE SURVIVAL; FEMALE; HUMAN; INFANT; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; MYCOSIS; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; RESPIRATORY FAILURE; RHABDOMYOSARCOMA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; DISEASE FREE SURVIVAL; MULTIMODALITY CANCER THERAPY; PRESCHOOL CHILD; PROCEDURES; SECONDARY;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFANT; MALE; RHABDOMYOSARCOMA; TREATMENT OUTCOME; VINCRISTINE;

EID: 77952583590     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.02.051     Document Type: Article

References (30)

1. Breneman J.C., Lyden E., Pappo A.S., et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma - a report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 21 (2003) 78-84
2. Crist W.M., Anderson J.R., Meza J.L., et al. Intergroup Rhabdomyosarcoma, study-IV: results for patients with nonmetastatic disease. J Clin Oncol 19 (2001) 3091-3102
3. Carli M., Colombatti R., Oberlin O., et al. European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors. J Clin Oncol 22 (2004) 4787-4794 [Erratum 2005;23:248]
4. Smith M.A., and Anderson B.D. A window on reality?. J Clin Oncol 22 (2004) 1360-1362
5. National Cancer Institute: Common Toxicity Criteria version 2.0 (CTC). ; 1999.
6. Newcombe R.G., and Altman D.G. Proportions and their differences. In: Altman D.G., Machin D., Bryant T.N., and Gardner M.J. (Eds). Statistics with confidence (2000), BMJ Publications, London 45-56
7. Machin D., Cheung Y.B., and Parmar M.K.B. Survival analysis: a practical approach (2006), John Wiley, Chichester
8. Chisholm J.C., Machin D., Mc Dowell H., et al. Efficacy of carboplatin in a phase II window study to children and adolescence with newly diagnosed metastatic soft tissue sarcoma. Eur J Cancer 43 (2007) 2537-2544
9. Bergeron C., Thiesse P., Rey A., et al. Re visiting the role of doxorubicin in the treatment of rhabdomyosarcoma: an up-front window study in newly diagnosed children with high-risk metastatic disease. Eur J Cancer 44 (2008) 427-431
10. Raney R.B., Tefft M., Maurer H.M., et al. Disease patterns and survival rate in children with metastatic soft-tissue sarcoma. A report from the Intergroup Rhabdomyosarcoma Study (IRS) I. Cancer 62 (1988) 1257-1266
11. Crist W.M., Garnsey L., Beltangady M.S., et al. Prognosis in children with rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Studies I and II. Intergroup Committee. J Clin Oncol 8 (1990) 443-452
12. Koscielniek E., Harms D., Henze G., et al. Results of treatment for soft tissue sarcoma in childhood and adolescence. A final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86. J Clin Oncol 17 (1999) 3706-3719
13. Oberlin O., Rey A., Lyden E., et al. Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. J Clin Oncol 26 (2008) 2384-2389
14. Pappo A.S., Bowman L.C., Furman W.L., et al. A phase II trial of high-dose methotrexate in previously untreated children and adolescents with high-risk unresectable or metastatic rhabdomyosarcoma. J Pediatr Hematol Oncol 19 (1997) 438-442
15. Walterhouse D.O., Hoover M.L., Marymont M.A., et al. High-dose chemotherapy followed by peripheral blood stem cell rescue for metastatic rhabdomyosarcoma: the experience at Chicago Children's Memorial Hospital. Med Pediatr Oncol 32 (1999) 88-92
16. Carli M., Colombatti R., Oberlin O., et al. High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma. J Clin Oncol 17 (1999) 2796-2803
17. Meyers P. High-dose therapy with autologous stem cell rescue for pediatric sarcomas. Curr Opin Oncol 16 (2004) 120-125
18. Lager J.L., Lyden E.R., Anderson J.R., et al. Pooled analysis of Phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report form the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol 24 (2006) 3415-3422
19. Horowitz M.E., Etcubanas E., Christensen E., et al. Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: a model for anticancer drug development. J Clin Oncol 6 (1988) 306-314
20. Koscielniak E., Klingebiel T.H., Peters C., et al. Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/Austrian Pediatric Bone Marrow Transplantation Group. Bone Marrow Transplant 19 (1997) 227-231
21. Lafay-Cousin L., Hartmann O., Plouvier P., et al. High-dose thiotepa and hematopoietic stem cell transplantation in pediatric malignant mesenchymal tumors: a phase II study. Bone Marrow Transplant 26 (2000) 627-632
22. Joshi D., Anderson J.R., Paidas C., et al. Age is an independent prognostic factor in Rhabdomyosarcoma: a report from the soft tissue sarcoma committee of the children's oncology group. Pediatr Blood Cancer 42 (2004) 64-73
23. Klingebiel T., Boos J., Beske F., et al. Treatment for children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: report of the HD CWS-96 trial. Pediatr Blood Cancer 50 (2008) 739-745
24. Peterson J.K., and Houghton P.J. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur J Cancer 40 (2004) 837-844
25. Burke M., Anderson J.R., Ka S.C., et al. Assessment of response to induction therapy and its influence on 5-year survival in Group III rhabdomyosarcoma: the Intergroup Rhabdomyosarcoma Study-IV experience - a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol 25 (2007) 4909-4913
26. Sorensen P.H., Lynch J.C., Qualman S.J., et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group. J Clin Oncol 20 (2002) 2672-2679
27. Blandford M.C., Barr F.G., Lynch J.C., et al. Rhabdomyosarcomas utilize developmental, myogenic growth factors for disease advantage: a report from the Children's Oncology Group. Pediatr Blood Cancer 46 (2006) 329-338
28. Seltz G., Warmann S.W., Vokuhi C.O., et al. Effects of standard chemotherapy on tumor growth and regulation of multidrug resistance genes and proteins in childhood rhabdomyosarcoma. Pediatr Surg Int 23 (2007) 431-439
29. McDowell H.P., Meco D., Riccardi A., et al. Imatinib mesylate potentiates topotecan antitumour activity in rhabdomyosarcoma preclinical models. Int J Cancer 120 (2007) 1141-1149
30. Diomedi-Camassei F., McDowell H.P., De Ioris M.A., et al. Clinical significance of CXC chemokine receptor-4 (CXCR4) and c-Met in childhood rhabdomyosarcoma. Clin Cancer Res 14 (2008) 4119-4127